Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized clinical trials

Cardiology Journal

Volumn 19, Issue 3, 2012, Pages 230-242

  Kubica, Jacek ^a   Koziński, Marek ^a   Navarese, Eliano P ^a   Tantry, Udaya S ^b   Grześk, Grzegorz ^a   Fabiszak, Tomasz ^a   Kubica, Aldona ^a   Światkiewicz, Iwona ^a   Bliden, Kevin P ^b   Gurbel, Paul A ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Intracoronary abciximab; Myocardial infarction; Primary PCI

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; HIRULOG; TIROFIBAN; VON WILLEBRAND FACTOR;

BLEEDING; CONTINUOUS INFUSION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INTRACORONARY INFUSION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; THROMBECTOMY; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION ROUTES; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 84861983175     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: 10.5603/CJ.2012.0044     Document Type: Review

References (57)

1. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J, 2010; 31: 2501-2555.
2. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2009; 54: 2205-2241.
3. Hagemeyer CE, Peter K. Targeting the platelet integrin GPIIb//IIIa. Curr Pharm Des, 2010; 16: 4119-4133.
4. Thiele H, Wöhrle J, Hambrecht R et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet, 2012; 379: 923-931.
5. Iversen AZ, Galatius S, Abildgaard U et al. Intracoronary Compared to Intravenous Abciximab in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention Reduces Mortality, Target Vessel Revascularization and Reinfarction after 1 Year. Cardiology, 2011; 120: 43-49.
6. Eitel I, Friedenberger J, Fuernau G et al. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI). Clin Res Cardiol, 2011; 100: 425-432.
7. Stone GW, Maehara A, Witzenbichler B et al. Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial. JAMA, 2012; DOI:10.1001/jama.2012.421.
8. Desch S, Siegemund A, Scholz U et al. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Clin Res Cardiol, 2012; 101: 117-124.
9. Buszman PP, Wojakowski W, Milewski K et al. Controlled Reperfusion with Intravenous Bivalirudin and Intracoronary Abciximab Combination Therapy in the Porcine Myocardial Infarction Model. Thromb Res, 2011; DOI: 10.1016/j.thromres. 2011.10.020.
10. Eitel I, Desch S, Schindler K, Fuernau G, Schuler G, Thiele H. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Int J Cardiol, 2011; 153: 21-25.
11. Navarese EP, Kozinski M, Obonska K et al. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. Platelets, 2011; DOI: 10.3109/09537104.2011.619602.
12. Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol, 2011; 108: 1244-1251.
13. Shimada YJ, Nakra NC, Fox JT, Kanei Y. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol, 2012; 109: 624-628.
14. Piccolo R, Gu YL, Iversen AZ et al. Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient data pooled analysis of randomised studies. Heart, 2012; DOI: 10.1136/heartjnl-2011--301101.
15. Wang Y, Wu B, Shu X. Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction. Am J Cardiol, 2012; 109: 1124-1130.
16. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis, 2007; 23: 57-63.
17. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation, 1994; 90: 1757-1764.
18. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation, 1998; 97: 1680-1688.
19. Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther, 2002; 71: 186-195.
20. Marciniak SJ Jr, Mascelli MA, Furman MI et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost, 2002; 87: 1020-1025.
21. Hantgan RR, Moussa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res, 1998; 89: 271-279.
22. Collet JP, Mishal Z, Soria J et al. Disaggregation of in vitro platelet-rich clots by abciximab increases fibrinogen exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol, 2001; 21: 142-148.
23. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb/IIIa. Blood, 1994; 83: 1006-1016.
24. Cohen I, Berk DL, White JG. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb/IIIa complex on the development of clot tension. Blood, 1989; 73: 1880-1887.
25. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation, 2010; 121: 784-791.
26. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest, 1996; 98: 863-874.
27. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (Reo- Pro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/III and avb3 integrins. Circulation, 1998; 98: 1085-1091.
28. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(v) beta3 in vascular biology. Thromb Haemost, 1998; 80: 726-734.
29. Altieri DC, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol, 1988; 141: 2656-2660.
30. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol, 1999; 34: 1420-1426.
31. Pant S, Neupane P, Ramesh KC, Barakoti M. Post percutaneous coronary intervention antiplatelet therapy: Current perceptions, prospects and perplexity. Cardiol J, 2011; 18: 712-717.
32. Tompkins C, Henrikson CA. Optimal strategies for the management of antiplatelet and anticoagulation medications prior to cardiac device implantation. Cardiol J, 2011; 18: 103-109.
33. Wöhrle J, Grebe OC, Nusser T et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation, 2003; 107: 1840-1843.
34. Kakkar AK, Moustapha A, Hanley HG et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv, 2004; 61: 31-34.
35. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv, 2004; 62: 186-192.
36. Romagnoli E, Burzotta F, Trani C et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol, 2005; 105: 250-255.
37. Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ. Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial [in Spanish]. Rev Esp Cardiol, 2006; 59: 567-574.
38. Thiele H, Schindler K, Friedenberger J et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation, 2008; 118: 49-57.
39. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P et al. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention Effects on soluble CD40 ligand concentrations. Atherosclerosis, 2009; 206: 523-527.
40. Bertrand OF, Rodés-Cabau J, Larose E et al. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A subanalysis of the EASY trial. Int J Cardiol, 2009; 136: 165-170.
41. Gu YL, Kampinga MA, Wieringa WG et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation, 2010; 122: 2709-2717.
42. Bertrand OF, Rodés-Cabau J, Larose E et al. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Am J Cardiol, 2010; 105: 1520-1527.
43. Iversen A, Abildgaard U, Galloe A et al. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial. J Interv Cardiol, 2011; 24: 105-111.
44. Prati F, Capodanno D, Pawlowski T et al. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. J Am Coll Cardiol Cardiovasc Interv, 2010; 3: 928-934.
45. Dave RM. Improving outcome of STEMI PCI: Preliminary results of crystal AMI trial. http://www.clinicaltrialresults.org//Slides/CRYSTAL_Slides.ppt
46. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol, 2010; 22: 278-282.
47. Navarese EP, Koziński M, Pafundi T et al. Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology. Cardiol J, 2011; 18: 3-7.
48. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb/IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J, 2009; 30: 2705-2713.
49. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. www.cochrane.org/resources//handbook/ [updated June 2011].
50. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 2009; 339: b2700.
51. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials, 1986; 7: 267-275.
52. Egger M, Smith GD. Bias in location and selection of studies. BMJ, 1998; 31: 61-66.
53. Kubica A, Kozinski M, Navarese EP, Grzesk G, Goch A, Kubica J. Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions. Curr Med Res Opin, 2011; 27: 2133-2144.
54. Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI (ICAT). http://clinicaltrials.gov/ct2/show/NCT01404507?term=ICAT&rank=1.
55. Sardella G, Sangiorgi GM, Mancone M et al. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale. J Cardiovasc Med (Hagerstown), 2010; 11: 529-535.
56. Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab (TOLEDO1). http://clinicaltrials.gov/ct2/show/NCT01383785?term=TOLEDO-1&rank=1.
57. A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI (EASY-RESCUE). http://clinicaltrials.gov/ct2/show/NCT00440895?term==EASY-RESCUE&rank=1.